1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Biologic therapies are reshaping psoriasis management across global healthcare settings, offering targeted solutions that improve long-term outcomes while compelling industry stakeholders to adapt strategies for access, affordability, and innovation.
Market Snapshot: Biologic Psoriasis Therapy Market
The biologic psoriasis therapy market continues to expand rapidly, driven by breakthrough cytokine inhibitors and the introduction of biosimilars. Market growth is fueled by favorable adoption among healthcare providers and increased recognition of the benefits of personalized, precision-targeted approaches. Evolving regulatory frameworks and advancements in drug manufacturing are further contributing, while market participants navigate shifting tariff landscapes and focus on optimizing cost structures and improved patient access.
Scope & Segmentation
This research provides a comprehensive analysis of market dynamics across drug classes, administration routes, distribution channels, patient demographics, and key regions.
- Drug Class: Interleukin 12/23 inhibitors (ustekinumab), Interleukin 17 inhibitors (brodalumab, ixekizumab, secukinumab), Interleukin 23 inhibitors (guselkumab, risankizumab, tildrakizumab), Tumor necrosis factor alpha inhibitors (adalimumab, etanercept, infliximab)
- Route of Administration: Intravenous infusion, Subcutaneous injection
- Distribution Channel: Hospital pharmacies, Retail pharmacies, Specialty pharmacies
- Patient Age Group: Adult patients, Pediatric patients
- Geographies: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
- Featured Companies: AbbVie Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., UCB S.A., Merck KGaA, Boehringer Ingelheim International GmbH, Celltrion, Inc., Samsung Bioepis Co., Ltd.
Key Takeaways
- Precision biologics are fundamentally changing treatment paradigms, offering enhanced skin clearance, improved patient quality of life, and more effective long-term management than traditional systemic therapies.
- Growing biosimilar adoption and the maturation of secondary markets are intensifying competition, prompting both innovator and generic manufacturers to invest in differentiated patient support and device innovation.
- Strategic partnerships—spanning manufacturers, payers, providers, and academia—are accelerating pipeline diversification, advancing next-generation drug formats, and facilitating integration of real-world evidence into decision-making.
- Segmentation by drug class, administration route, and patient demographics is increasingly leveraged to tailor product positioning and guide market entry, ensuring responsive and value-driven commercialization strategies.
- Regional dynamics, from robust reimbursement systems in North America and Western Europe to capacity-building in emerging markets, require nuanced engagement models and adaptive distribution strategies.
Impact of Tariff Policies
Recent United States tariff changes are reshaping sourcing and manufacturing decisions for biologic drugs. Manufacturers are adapting through supplier negotiations, investment in domestic production, and flexible platform adoption. These shifts aim to stabilize supply chains and manage costs, while ongoing advocacy for tariff exemptions continues to influence sector operating models.
Methodology & Data Sources
This analysis integrates primary interviews with dermatology experts, industry executives, payers, and advocacy leaders, combined with secondary research from regulatory filings, publications, clinical trial registries, and press releases. Data triangulation validated emerging themes, and expert validation workshops ensured practical relevance and accuracy throughout the research process.
Why This Report Matters
- Enables informed strategic planning for executives navigating biologic market complexity, competition, and regulatory challenges.
- Offers segment-specific and regional insights to optimize product development, distribution, and partnership strategy.
- Supports decision-makers in aligning commercial models with evolving market trends and future innovation pathways.
Conclusion
The biologic psoriasis therapy market presents both dynamic opportunities and operational challenges. By leveraging targeted innovation, strategic alliances, and data-driven approaches, industry leaders can sustain growth and advance patient outcomes in an evolving landscape.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of IL-23 inhibitors with sustained efficacy in moderate-to-severe psoriasis
5.2. Real-world evidence of safety profiles for biosimilars versus originator biologics in long-term psoriasis treatment
5.3. Impact of COVID-19 related telemedicine adoption on long-term patient adherence to biologic regimens
5.4. Pipeline innovations targeting oral tyrosine kinase inhibitors as alternative treatments for psoriasis
5.5. Adoption of pharmacogenomic-driven personalized dosing algorithms to optimize biologic therapy outcomes
5.6. Expansion of patient support services and digital health platforms enhancing biologic self-administration adherence
5.7. Competitive landscape shift driven by bispecific antibodies co-targeting IL-17 and TNF pathways in development
5.8. Market uptake influenced by evolving payer reimbursement policies and value-based contracts for biologics
5.9. Increasing focus on real-world pharmacoeconomic studies to demonstrate value of high-cost biologic therapies
5.2. Real-world evidence of safety profiles for biosimilars versus originator biologics in long-term psoriasis treatment
5.3. Impact of COVID-19 related telemedicine adoption on long-term patient adherence to biologic regimens
5.4. Pipeline innovations targeting oral tyrosine kinase inhibitors as alternative treatments for psoriasis
5.5. Adoption of pharmacogenomic-driven personalized dosing algorithms to optimize biologic therapy outcomes
5.6. Expansion of patient support services and digital health platforms enhancing biologic self-administration adherence
5.7. Competitive landscape shift driven by bispecific antibodies co-targeting IL-17 and TNF pathways in development
5.8. Market uptake influenced by evolving payer reimbursement policies and value-based contracts for biologics
5.9. Increasing focus on real-world pharmacoeconomic studies to demonstrate value of high-cost biologic therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Biologic Medications for Psoriasis Market, by Drug Class
8.1. Introduction
8.2. Interleukin 12/23 Inhibitors
8.2.1. Ustekinumab
8.3. Interleukin 17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. Interleukin 23 Inhibitors
8.4.1. Guselkumab
8.4.2. Risankizumab
8.4.3. Tildrakizumab
8.5. Tumor Necrosis Factor Alpha Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
8.2. Interleukin 12/23 Inhibitors
8.2.1. Ustekinumab
8.3. Interleukin 17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. Interleukin 23 Inhibitors
8.4.1. Guselkumab
8.4.2. Risankizumab
8.4.3. Tildrakizumab
8.5. Tumor Necrosis Factor Alpha Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. Biologic Medications for Psoriasis Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Biologic Medications for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Pharmacies
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Pharmacies
11. Biologic Medications for Psoriasis Market, by Patient Age Group
11.1. Introduction
11.2. Adult Patients
11.3. Pediatric Patients
11.2. Adult Patients
11.3. Pediatric Patients
12. Americas Biologic Medications for Psoriasis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biologic Medications for Psoriasis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biologic Medications for Psoriasis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Novartis AG
15.3.3. Eli Lilly and Company
15.3.4. Johnson & Johnson
15.3.5. Amgen Inc.
15.3.6. UCB S.A.
15.3.7. Merck KGaA
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Celltrion, Inc.
15.3.10. Samsung Bioepis Co., Ltd.
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Novartis AG
15.3.3. Eli Lilly and Company
15.3.4. Johnson & Johnson
15.3.5. Amgen Inc.
15.3.6. UCB S.A.
15.3.7. Merck KGaA
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Celltrion, Inc.
15.3.10. Samsung Bioepis Co., Ltd.
List of Figures
FIGURE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHAI
FIGURE 24. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHSTATISTICS
FIGURE 25. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHCONTACTS
FIGURE 26. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHAI
FIGURE 24. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHSTATISTICS
FIGURE 25. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHCONTACTS
FIGURE 26. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLIO
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY GUSELKUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. CANADA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. MEXICO BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. GERMANY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. FRANCE BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. ITALY BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 12/23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY INTERLEUKIN 23 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN BIOLOGIC MEDICATIONS FOR PSORIASIS MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITORS, 2018-2024 (USD MILLIO
Samples
LOADING...
Companies Mentioned
The companies profiled in this Biologic Medications for Psoriasis market report include:- AbbVie Inc.
- Novartis AG
- Eli Lilly and Company
- Johnson & Johnson
- Amgen Inc.
- UCB S.A.
- Merck KGaA
- Boehringer Ingelheim International GmbH
- Celltrion, Inc.
- Samsung Bioepis Co., Ltd.
